Objective: In this study, we investigated the importance of gle-ason score in detecting bone metastasis in prostate adenocarcino-ma patients whose prostate-specific antigen (PSA) level ≤ 20 ng / ml Materials and Methods: Prostate adenocarcinoma cases diago-sed by 10-quadrant transrectal ultrasound-guided prostate biopsy were divided into 2 groups of total gleason score ≤6 (30 patients) and total gleason score >6 (50 patients). Both groups compared in terms of age, total PSA and metastasis on bone scintigraphy.
Results: The mean age was 69.60 ± 6.56 in patients with gle-ason score ≤6 and 70.68 ± 8.34 in patients with gleason score > 6 (p=0.153). The mean PSA level was 12.10 ± 4.57 mg/ dl in patients with gleason score ≤ 6 and 13.11 ± 4.53 in patients with gleason score >6 (p=0.652). There was no singnificant difference in terms of age and total PSA however metastasis on bone scintigraphy was significantly higher in the patient with gleason score>6 (p<0,001).
Conclusion: Bone scintigraphy is not used routinely in patients with prostate cancer whose PSA level ≤ 20 ng/ml for metastatic eva-luation. In this study, we detected significantly higher rate of metas-tasis on bone scintigraphy in the patient with gleason score>6 and PSA level ≤ 20 ng/ml. We suggest bone scintigraphy in prostate can-cer patients with gleason score > 6 for metastatic evaluation even if PSA level is less than or equal to 20 ng/ml.
Key Words: Prostate cancer, Gleason score, Prostate spesific antigen, Bone scintigraphy
Abstract
Objective: In this study, we investigated the importance of gle-ason score in detecting bone metastasis in prostate adenocarcino-ma patients whose prostate-specific antigen (PSA) level ≤ 20 ng / ml Materials and Methods: Prostate adenocarcinoma cases diago-sed by 10-quadrant transrectal ultrasound-guided prostate biopsy were divided into 2 groups of total gleason score ≤6 (30 patients) and total gleason score >6 (50 patients). Both groups compared in terms of age, total PSA and metastasis on bone scintigraphy.
Results: The mean age was 69.60 ± 6.56 in patients with gle-ason score ≤6 and 70.68 ± 8.34 in patients with gleason score > 6 (p=0.153). The mean PSA level was 12.10 ± 4.57 mg/ dl in patients with gleason score ≤ 6 and 13.11 ± 4.53 in patients with gleason score >6 (p=0.652). There was no singnificant difference in terms of age and total PSA however metastasis on bone scintigraphy was significantly higher in the patient with gleason score>6 (p<0,001).
Conclusion: Bone scintigraphy is not used routinely in patients with prostate cancer whose PSA level ≤ 20 ng/ml for metastatic eva-luation. In this study, we detected significantly higher rate of metas-tasis on bone scintigraphy in the patient with gleason score>6 and PSA level ≤ 20 ng/ml. We suggest bone scintigraphy in prostate can-cer patients with gleason score > 6 for metastatic evaluation even if PSA level is less than or equal to 20 ng/ml.
Key Words: Prostate cancer, Gleason score, Prostate spesific antigen, Bone scintigraphy